BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget 2016;7:65696-706. [PMID: 27582545 DOI: 10.18632/oncotarget.11602] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Wang X, Xu L, Zhang J. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma. Cancer Med 2022. [PMID: 36043552 DOI: 10.1002/cam4.5187] [Reference Citation Analysis]
2 Schwark K, Messinger D, Cummings JR, Bradin J, Kawakibi A, Babila CM, Lyons S, Ji S, Cartaxo RT, Kong S, Cantor E, Koschmann C, Yadav VN. Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine. Front Oncol 2022;12:922928. [DOI: 10.3389/fonc.2022.922928] [Reference Citation Analysis]
3 Buccoliero AM, Giunti L, Moscardi S, Castiglione F, Provenzano A, Sardi I, Scagnet M, Genitori L, Caporalini C. Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series. Genes 2022;13:624. [DOI: 10.3390/genes13040624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen Y, Miao L, Lin H, Zhuo Z, He J. The role of m6A modification in pediatric cancer. Biochim Biophys Acta Rev Cancer 2022;:188691. [PMID: 35122883 DOI: 10.1016/j.bbcan.2022.188691] [Reference Citation Analysis]
5 Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer 2022;3:11-24. [PMID: 35121998 DOI: 10.1038/s43018-021-00319-0] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Ferreras C, Fernández L, Clares-Villa L, Ibáñez-Navarro M, Martín-Cortázar C, Esteban-Rodríguez I, Saceda J, Pérez-Martínez A. Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours. Cells 2021;10:2940. [PMID: 34831165 DOI: 10.3390/cells10112940] [Reference Citation Analysis]
7 Peng G, Wang Y, Ge P, Bailey C, Zhang P, Zhang D, Meng Z, Qi C, Chen Q, Chen J, Niu J, Zheng P, Liu Y, Liu Y. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin. J Exp Clin Cancer Res 2021;40:278. [PMID: 34470658 DOI: 10.1186/s13046-021-02082-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, Beroukhim R, Bandopadhayay P, Chi S, Ramkissoon SH, Mullan B, Bruzek AK, Gauthier A, Garcia T, Atchison C, Marini B, Fouladi M, Parsons DW, Leary S, Mueller S, Ligon KL, Koschmann C. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol 2019;21:968-80. [PMID: 30805642 DOI: 10.1093/neuonc/noz022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
9 Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B, Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard M, Robertson PL, Garton HJ, Wahl DR, Parmar H, Sarkaria JN, Kline C, Mueller S, Nicolaides T, Glasser C, Leary SE, Venneti S, Kumar-Sinha C, Chinnaiyan AM, Mody R, Pai MP, Phoenix TN, Marini BL, Koschmann C. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. J Clin Invest 2020;130:5313-25. [PMID: 32603316 DOI: 10.1172/JCI133310] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
10 Chen CCL, Deshmukh S, Jessa S, Hadjadj D, Lisi V, Andrade AF, Faury D, Jawhar W, Dali R, Suzuki H, Pathania M, A D, Dubois F, Woodward E, Hébert S, Coutelier M, Karamchandani J, Albrecht S, Brandner S, De Jay N, Gayden T, Bajic A, Harutyunyan AS, Marchione DM, Mikael LG, Juretic N, Zeinieh M, Russo C, Maestro N, Bassenden AV, Hauser P, Virga J, Bognar L, Klekner A, Zapotocky M, Vicha A, Krskova L, Vanova K, Zamecnik J, Sumerauer D, Ekert PG, Ziegler DS, Ellezam B, Filbin MG, Blanchette M, Hansford JR, Khuong-Quang DA, Berghuis AM, Weil AG, Garcia BA, Garzia L, Mack SC, Beroukhim R, Ligon KL, Taylor MD, Bandopadhayay P, Kramm C, Pfister SM, Korshunov A, Sturm D, Jones DTW, Salomoni P, Kleinman CL, Jabado N. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell 2020;183:1617-1633.e22. [PMID: 33259802 DOI: 10.1016/j.cell.2020.11.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
11 Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D, Krek A, Ma W, Zhu Y, Ji J, Calinawan A, Whiteaker JR, Colaprico A, Stathias V, Omelchenko T, Song X, Raman P, Guo Y, Brown MA, Ivey RG, Szpyt J, Guha Thakurta S, Gritsenko MA, Weitz KK, Lopez G, Kalayci S, Gümüş ZH, Yoo S, da Veiga Leprevost F, Chang HY, Krug K, Katsnelson L, Wang Y, Kennedy JJ, Voytovich UJ, Zhao L, Gaonkar KS, Ennis BM, Zhang B, Baubet V, Tauhid L, Lilly JV, Mason JL, Farrow B, Young N, Leary S, Moon J, Petyuk VA, Nazarian J, Adappa ND, Palmer JN, Lober RM, Rivero-Hinojosa S, Wang LB, Wang JM, Broberg M, Chu RK, Moore RJ, Monroe ME, Zhao R, Smith RD, Zhu J, Robles AI, Mesri M, Boja E, Hiltke T, Rodriguez H, Zhang B, Schadt EE, Mani DR, Ding L, Iavarone A, Wiznerowicz M, Schürer S, Chen XS, Heath AP, Rokita JL, Nesvizhskii AI, Fenyö D, Rodland KD, Liu T, Gygi SP, Paulovich AG, Resnick AC, Storm PB, Rood BR, Wang P; Children’s Brain Tumor Network., Clinical Proteomic Tumor Analysis Consortium. Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell 2020;183:1962-1985.e31. [PMID: 33242424 DOI: 10.1016/j.cell.2020.10.044] [Cited by in Crossref: 19] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
12 Tsvankin V, Hashizume R, Katagi H, Herndon JE, Lascola C, Venkatraman TN, Picard D, Burrus B, Becher OJ, Thompson EM. ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma. Neurosurgery 2020;86:742-51. [PMID: 31225627 DOI: 10.1093/neuros/nyz212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Amero P, Khatua S, Rodriguez-Aguayo C, Lopez-Berestein G. Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology. Cancers (Basel) 2020;12:E2889. [PMID: 33050158 DOI: 10.3390/cancers12102889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Gonçalves FG, Alves CAPF, Vossough A. Updates in Pediatric Malignant Gliomas. Top Magn Reson Imaging 2020;29:83-94. [PMID: 32271285 DOI: 10.1097/RMR.0000000000000235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Georgescu MM, Islam MZ, Li Y, Circu ML, Traylor J, Notarianni CM, Kline CN, Burns DK. Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma. Acta Neuropathol Commun 2020;8:111. [PMID: 32680567 DOI: 10.1186/s40478-020-00992-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
16 Packer RJ, Kilburn L. Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. J Child Neurol 2020;35:791-8. [PMID: 32552173 DOI: 10.1177/0883073820931635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
17 Guntner AS, Peyrl A, Mayr L, Englinger B, Berger W, Slavc I, Buchberger W, Gojo J. Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathol Commun 2020;8:78. [PMID: 32493453 DOI: 10.1186/s40478-020-00953-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
18 Cho HJ, Zhao J, Jung SW, Ladewig E, Kong DS, Suh YL, Lee Y, Kim D, Ahn SH, Bordyuh M, Kang HJ, Sa JK, Seo YJ, Kim ST, Lim DH, Dho YS, Lee JI, Seol HJ, Choi JW, Park WY, Park CK, Rabadan R, Nam DH. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. Neuro Oncol 2019;21:47-58. [PMID: 30085274 DOI: 10.1093/neuonc/noy123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
19 Metibemu DS, Akinloye OA, Akamo AJ, Ojo DA, Okeowo OT, Omotuyi IO. Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egypt J Med Hum Genet 2019;20. [DOI: 10.1186/s43042-019-0035-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
20 Taylor OG, Brzozowski JS, Skelding KA. Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets. Front Oncol 2019;9:963. [PMID: 31616641 DOI: 10.3389/fonc.2019.00963] [Cited by in Crossref: 79] [Cited by in F6Publishing: 108] [Article Influence: 26.3] [Reference Citation Analysis]
21 Goodarzi A, Garza N, Lechpammer M, Anthony R, Zwienenberg M. The molecular oncology of bilateral high-grade thalamic astrocytomas in children. Childs Nerv Syst 2019;35:2047-54. [PMID: 31522255 DOI: 10.1007/s00381-019-04372-0] [Reference Citation Analysis]
22 Kaya Terzi N, Yılmaz İ, Öz AB. The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis. Balkan Med J 2019;36:222-8. [PMID: 30592195 DOI: 10.4274/balkanmedj.galenos.2018.2018.1221] [Reference Citation Analysis]
23 Kaneva K, Yeo KK, Hawes D, Ji J, Biegel JA, Nelson MD, Bluml S, Krieger MD, Erdreich-Epstein A. Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution. JCO Precis Oncol 2019;3. [PMID: 31179415 DOI: 10.1200/PO.18.00138] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Ip CKM, Ng PKS, Jeong KJ, Shao SH, Ju Z, Leonard PG, Hua X, Vellano CP, Woessner R, Sahni N, Scott KL, Mills GB. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nat Commun 2018;9:4583. [PMID: 30389923 DOI: 10.1038/s41467-018-06949-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
25 Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer 2018;65:e27035. [PMID: 29512900 DOI: 10.1002/pbc.27035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
26 Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018;17:36. [PMID: 29455664 DOI: 10.1186/s12943-018-0801-5] [Cited by in Crossref: 105] [Cited by in F6Publishing: 152] [Article Influence: 26.3] [Reference Citation Analysis]
27 Vanan MI, Underhill DA, Eisenstat DD. Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas. Neurotherapeutics 2017;14:274-83. [PMID: 28233220 DOI: 10.1007/s13311-017-0514-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
28 Helbig D, Quaas A, Mauch C, Merkelbach-Bruse S, Büttner R, Emberger M, Wobser M, Rüsseler V, Pütz K, Binot E, Rehker J, Budczies J, Ihle MA. Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 2017;8:109457-67. [PMID: 29312620 DOI: 10.18632/oncotarget.22691] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
29 Linzey JR, Marini B, McFadden K, Lorenzana A, Mody R, Robertson PL, Koschmann C. Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma". NPJ Precis Oncol 2017;1:29. [PMID: 29872711 DOI: 10.1038/s41698-017-0036-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
30 Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. Crit Rev Oncol Hematol 2017;118:1-6. [PMID: 28917265 DOI: 10.1016/j.critrevonc.2017.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
31 El-Ayadi M, Ansari M, Sturm D, Gielen GH, Warmuth-Metz M, Kramm CM, von Bueren AO. High-grade glioma in very young children: a rare and particular patient population. Oncotarget. 2017;8:64564-64578. [PMID: 28969094 DOI: 10.18632/oncotarget.18478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
32 Lenting K, Verhaak R, Ter Laan M, Wesseling P, Leenders W. Glioma: experimental models and reality. Acta Neuropathol 2017;133:263-82. [PMID: 28074274 DOI: 10.1007/s00401-017-1671-4] [Cited by in Crossref: 155] [Cited by in F6Publishing: 144] [Article Influence: 31.0] [Reference Citation Analysis]